NodThera, a decade-old NLRP3 player, plans Phase 3 and a rebrand

After tinkering with the biology of the broadly appealing anti-inflammatory NLRP3 pathway, NodThera is now plotting its pivotal trial plans for 2027. The decade-old biotech said Wednesday it is rebranding to Rezera ...